HOME >> BIOLOGY >> NEWS
Hepatitis C complicated by morphine withdrawal

Philadelphia, PAResearchers at the University of Pennsylvania have demonstrated that morphine withdrawal complicates hepatitis C by suppressing IFN-alpha-mediated immunity and enhancing virus replication. The paper by Wang et al., Morphine withdrawal enhances hepatitis C virus (HCV) replicon expression, appears in the November issue of The American Journal of Pathology and is accompanied by a commentary.

Hepatitis C virus (HCV) is common among intravenous drug users, with 70 to 80% of abusers infected in the United States. This high association has peaked interest in determining the effects of drug abuse, specifically opiates, on progression of the disease. The discovery of such an association would impact treatment of both HCV infection and drug abuse.

Dr. Wen-Zhe Ho has been interested in such interplay for some time. His laboratory has previously shown using cell culture that morphine enhances virus replication and inhibits IFN-alpha (a natural anti-viral factor produced by immune, as well as host cells, and the only one approved in recombinant form for treating HCV infection). To further these results, his lab has used a cell model system to determine the consequences of morphine withdrawal, which is a common recurring event in opioid users.

Chuan-Qing Wang and colleagues examined the effects of morphine withdrawal (MW) on HCV-infected cultured liver cells by exposing cells to the drug for four days followed by its removal. They also assessed the effects of using naloxone, to block the opioid receptors, in conjunction with drug removal, i.e. precipitated morphine withdrawal (PW). To measure HCV replication, they used a virus-like replicon that mimics the events that occur in liver cells and expression of viral RNA and proteins that HCV uses. Although the replicon does not produce the infectious virus, the HCV replicon system represents the best available system for examining the impact of opiates on HCV at the time of their r
'"/>

Contact: Audra E. Cox
acox@asip.org
301-634-7409
American Journal of Pathology
28-Oct-2005


Page: 1 2

Related biology news :

1. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process
2. Hepatitis B drug can compromise HIV treatment
3. Hepatitis E takes a piggyback
4. New hope for Hepatitis C research
5. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
6. New insights into protein synthesis and Hepatitis C infections
7. Hepatitis B accounts for 40 percent of missing Asian women
8. Identification of a protein important for Hepatitis B replication
9. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
10. Hepatitis C virus linked to non-Hodgkins lymphoma
11. Efficacy of once-daily Avelox for complicated abdominal infections highlighted at ICAAC

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 24, 2020 , ... ... chronic inflammatory and fibrotic diseases, today announced that Dr. Stacie Canan has joined ... , Dr. Canan previously served as Executive Director of Global Health at Bristol ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently ... ideal for public health agencies of all sizes. With a focus on tracking ... individuals find appropriate health care, Mosio helps public health departments automate communications and ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society ... Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of ... a consortium of academic research centers in the United States and Europe with ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly ... closed on the purchase of greenfield for a new, expanded manufacturing facility. The ... 21 acres in the initial acquisition, with an option to purchase an additional ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... up to three different materials for use with CRM, neurostimulation, vascular, and related ... materials to meet specific design requirements, performance, and cost criteria; especially where solid ...
Breaking Biology Technology:
Cached News: